NewLink Genetics Corp. (NLNK)

7.11
NASDAQ : Health Technology
Prev Close 6.84
Day Low/High 6.85 / 7.42
52 Wk Low/High 5.90 / 25.17
Avg Volume 820.00K
Exchange NASDAQ
Shares Outstanding 37.08M
Market Cap 256.39M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Purchase NewLink Genetics Corp At $6, Earn 60.9% Annualized Using Options

Investors considering a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $8.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April put at the $6 strike, which has a bid at the time of this writing of $1.00.

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...

NewLink Genetics Outlines 2018 Business Priorities To Support Phase 3 Pivotal Trial Of Indoximod Plus PD-1 Inhibitors

NewLink Genetics Outlines 2018 Business Priorities To Support Phase 3 Pivotal Trial Of Indoximod Plus PD-1 Inhibitors

NewLink Genetics updates financial and clinical guidance

Notable Thursday Option Activity: NLNK, SMG, LAD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NewLink Genetics Corp , where a total volume of 8,561 contracts has been traded thus far today, a contract volume which is representative of approximately 856,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 117.7% of NLNK's average daily trading volume over the past month, of 727,295 shares.

Relative Strength Alert For NewLink Genetics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

NewLink Genetics Reports Third Quarter 2017 Financial Results And Updates Indoximod Program

NewLink Genetics Reports Third Quarter 2017 Financial Results And Updates Indoximod Program

- Management to Host Conference Call Today at 8:30 a.m. ET

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Interesting NLNK Put And Call Options For November 17th

Investors in NewLink Genetics Corp saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NLNK options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

NewLink Genetics Announces Proposed Public Offering Of Common Stock

NewLink Genetics Announces Proposed Public Offering Of Common Stock

NewLink Genetics Corporation ("NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares...

NewLink Genetics Announces Clinical Collaboration To Evaluate IO-Based Combination Therapies In Pancreatic Cancer

NewLink Genetics Announces Clinical Collaboration To Evaluate IO-Based Combination Therapies In Pancreatic Cancer

Phase 2, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, an immune checkpoint inhibitor, along with gemcitabine/ABRAXANE® (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE® versus gemcitabine/ABRAXANE®

NewLink Genetics Announces Clinical Collaboration To Evaluate IO-Based Combination Therapies In Pancreatic Cancer

NewLink Genetics Announces Clinical Collaboration To Evaluate IO-Based Combination Therapies In Pancreatic Cancer

NewLink Genetics Corporation (Nasdaq: NLNK) today announced that it has entered into a clinical collaboration agreement with AstraZeneca to evaluate the combination of indoximod, NewLink Genetics' small molecule IDO...

Commit To Purchase NewLink Genetics Corp At $8, Earn 27% Annualized Using Options

Investors eyeing a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $11.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2018 put at the $8 strike, which has a bid at the time of this writing of $1.25.

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.

Indoximod Plus Pembrolizumab Data From Phase 2 Trial In Advanced Melanoma (Graphic: Business Wire)

Indoximod Plus Pembrolizumab Data From Phase 2 Trial In Advanced Melanoma (Graphic: Business Wire)

NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics' IDO pathway inhibitor, in combination with the PD-1 pathway inhibitor,...

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

And a management shakeup helps push down NuVasive.

NewLink Genetics Reports Second Quarter 2017 Financial Results And Updates Indoximod Program

NewLink Genetics Reports Second Quarter 2017 Financial Results And Updates Indoximod Program

Management to Host Conference Call Today at 8:30 a.m. ET

TheStreet Quant Rating: D (Sell)